Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
Novartis invests in CAR-T production in China
by Jean-François Tremblay
October 7, 2018
| A version of this story appeared in
Volume 96, Issue 40
Novartis will inject $40 million into Cellular Biomedicine Group (CBMG), a Chinese firm that will produce Novartis’s Kymriah CAR T-cell treatment for people with cancer in China. Although Kymriah has yet to be approved in China, Novartis expects the government will give the go-ahead because China is home to the world’s largest group of people with the types of cancers that Kymriah treats. As part of the deal between the two companies, CBMG will receive an increasing percentage of the drug’s sales in China as the market grows.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter